Compare Stocks → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYCCNASDAQ:GEMPNASDAQ:MTFBNASDAQ:PHIONASDAQ:TRPX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$1.60-30.4%$2.31$1.41▼$13.20$3.03M0.5455,516 shs3.47 million shsGEMPGemphire Therapeutics$3.06-1.3%$4.97$0.24▼$1.49$45.51M2.82127,174 shs1,823 shsMTFBMOTIF BIO PLC/S$0.11$0.10$0.08▼$11.50N/AN/AN/A867,698 shsPHIOPhio Pharmaceuticals$0.71+4.4%$0.80$0.50▼$6.85$3.08M1.44454,855 shs217,368 shsTRPXTherapix Biosciences$0.10$0.23$0.25▼$4.69$351KN/A1.59 million shs95,212 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals-29.82%-13.51%-17.95%-24.53%-82.25%GEMPGemphire Therapeutics-1.29%-11.05%-30.22%-1.92%+354.01%MTFBMOTIF BIO PLC/S0.00%0.00%0.00%0.00%0.00%PHIOPhio Pharmaceuticals+5.22%+11.18%-3.29%+28.34%-78.67%TRPXTherapix Biosciences0.00%0.00%0.00%0.00%0.00%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCCCyclacel Pharmaceuticals1.0129 of 5 stars3.33.00.00.00.60.00.6GEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals2.1471 of 5 stars3.53.00.00.00.82.50.6TRPXTherapix BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals2.50Moderate Buy$21.001,212.50% UpsideGEMPGemphire TherapeuticsN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/APHIOPhio Pharmaceuticals3.00Buy$4.00466.57% UpsideTRPXTherapix BiosciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest GEMP, TRPX, PHIO, CYCC, and MTFB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/6/2024PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$420K5.03N/AN/A$0.57 per share2.81GEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$2.06 per shareN/ATRPXTherapix BiosciencesN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)GEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AMTFBMOTIF BIO PLC/SN/AN/A0.00∞N/AN/AN/AN/AN/APHIOPhio Pharmaceuticals-$10.83M-$5.93N/A∞N/AN/A-134.66%-105.86%5/9/2024 (Estimated)TRPXTherapix Biosciences-$4.79MN/A0.00∞N/AN/AN/AN/AN/ALatest GEMP, TRPX, PHIO, CYCC, and MTFB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023PHIOPhio PharmaceuticalsN/A-$0.17-$0.17-$0.17N/AN/A3/19/2024Q4 2023CYCCCyclacel Pharmaceuticals-$6.35-$6.23+$0.12-$6.23N/A$0.03 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ATRPXTherapix BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A0.910.91GEMPGemphire TherapeuticsN/A0.670.67MTFBMOTIF BIO PLC/SN/AN/AN/APHIOPhio PharmaceuticalsN/A5.705.71TRPXTherapix BiosciencesN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%GEMPGemphire Therapeutics17.53%MTFBMOTIF BIO PLC/SN/APHIOPhio Pharmaceuticals57.31%TRPXTherapix Biosciences14.32%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals8.47%GEMPGemphire Therapeutics22.70%MTFBMOTIF BIO PLC/SN/APHIOPhio Pharmaceuticals0.77%TRPXTherapix BiosciencesN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals2,0181.32 million1.21 millionOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableMTFBMOTIF BIO PLC/S7N/AN/ANot OptionablePHIOPhio Pharmaceuticals94.59 million4.56 millionNot OptionableTRPXTherapix Biosciences93.51 millionN/ANot OptionableGEMP, TRPX, PHIO, CYCC, and MTFB HeadlinesSourceHeadlineAnixa Biosciences Stock (NASDAQ:ANIX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - December 12 at 5:48 AMSagimet Biosciences Inc (SGMT)investing.com - August 23 at 7:29 AMPBIO Pressure BioSciences, Inc.seekingalpha.com - August 1 at 3:24 PMCannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOsthestreet.com - January 19 at 7:59 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCyclacel PharmaceuticalsNASDAQ:CYCCCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Gemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.MOTIF BIO PLC/SNASDAQ:MTFBMotif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.Phio PharmaceuticalsNASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Therapix BiosciencesNASDAQ:TRPX Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.